Screening Triage and Risk Stratification (I-share)

Improving Screening Triage in Older Postmenopausal HPV-screen-positive Women Aged 50-64 and Risk-stratification of Women Aged 23-64 After Excision

• To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load as triage markers in post-menopausal HPV-screen-positive women aged 50-64 years in the organized screening program to predict the risk of developing CIN2+. (work package 1)
• To investigate the performance of cytology, extended genotyping, p16/Ki67 dual stain cytology, DNA methylation and viral load six months after cervical excision to predict the long-term risk of residual/recurrent CIN2+ lesions among women aged 23-64 (work-package 2)

Study Overview

• Status: Recruiting
• Conditions: Cervix Cancer; Postmenopausal Women; HPV Testing
• Intervention / Treatment: Other: cytology, p16/ki67 dual stain cytology (DS), extended genotyping, DNA methylation, viral load,

Detailed Description

As HPV-positive women may have a transient infection which would be cleared with treatment, triage of HPV-positive women are needed to decrease the colposcopy referral. Liquid-based cytology (hereinafter cytology) are often used as triage for HPV-positive women. HPV 16/18 are the predominant HPV types in younger women and are for all aged referred directly for colposcopy. However as women age, hrHPV other types become more prevalent(10) and these types are triaged with cytology. However, as cytology undergo subjective interpretation and as it may have a decreased sensitivity in with increasing age(11, 12) cytology may not be the most optimal triage marker in postmenopausal women.

p16/Ki67 dual stain cytology (hereinafter DS) is another triage marker. p16 is a cell-cycle regulator protein and Ki67 is a proliferation-associated protein which under normal circumstances are mutual exclusive. Thus, in an HPV-transformed cell co-expression of p16 and Ki67 indicates cell deregulation and increased risk of cervical precancer.(13) In several studies DS have shown better sensitivity and negative predictive value (NPV) as compared to cytology in triaging HPV-positive women(14-17) and women with low-grade cytology (ASC-US and LSIL)(18-20).

Methylation of HPV-positive women benefits from a more objective evaluation than both cytology and DS and has in shown promising results in triaging HPV-positive women.(21) Most studies on DS and methylation have however, been conducted in younger women and studies evaluation the performance in postmenopausal women are needed.

Women diagnosed with CIN2+ undergo excisional treatment removing the lesions and thereby reducing the woman's risk of developing cervical cancer. The most frequently used method is loop electrosurgical excision procedure (LEEP). Despite treatment, women previously diagnosed with CIN3+ lesion are at greater risk of developing cervical cancer with the risk increasing with increasing age.(22) Surveillance after LEEP consist of test-of cure (i.e. cytology and HPV test) six months after LEEP in several countries.(23-27) Treatment of CIN2+ is however, not always successful and residual or recurrent high-grade disease (CIN2+) occurs on average in 8% (ranging from 4% to 18%) of treated women, with the majority of treatment failure occurring mainly the first two post-operative years.(28, 29) Persistent HPV infection and positive margins after LEEP are risk factors for residual or recurrent disease after LEEP(28). However, not all women are at the same risk of recurrent disease, but still managed the same way as women at higher risk and therefore a future risk-stratification are needed to individualize the follow-up pathways. Moreover, introduction of a risk-stratification in the follow-up pathway may also decrease the number of open-ended follow-up pathways. In a recent study in HPV-positive women 60-64 years only 26% had follow-up as recommended.(30)

• Study Type: Observational
• Enrollment (Anticipated): 5000

Contacts and Locations

• Study Contact: Name: mette tranberg, post doc; Phone Number: 40113676; Email: mettrani@rm.dk
• Study Contact Backup: Name: Line Winther Gustafson, MD; Phone Number: +4578420264; Email: Line.Winther@skejby.rm.dk

Study Locations

• Denmark
  • Central Denmark Region
    • Randers, Central Denmark Region, Denmark, 8930
      • Recruiting
      • Department of Pathology
      • Contact: mette tranberg, post doc; Phone Number: 40113676; Email: mettrani@rm.dk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 23 years to 64 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

Women aged 50-65 who have been tested HPV-screen positive

Women aged 23-64 who undergo test-of-cure or follow-up test after LEEP

Description

Inclusion Criteria:

• HPV-screen-positive (aged 50-64)
• Women who undergo test-of-cure (i.e. HPV and cytology) six months after LEEP in Central Denmark Region (aged 23-64)
• Women who undergo follow-up test (i.e. HPV and cytology) 12 months after LEEP
• A valid cytology-triage result (aged 23-64)

Exclusion Criteria:

• Listed in the registry as a person who have rejected to participate in research
• Invalid cytology and HPV result six months after LEEP
• No residual material available

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The number of women with CIN2+ diagnosed in either cervical biopsies or cone biopsy	The detection of underlying CIN2 or worse	at baseline ( within 3 months after index sample)
The number of women with CIN2+ diagnosed in either cervical biopsies or cone biopsy	The detection of underlying CIN2 or worse	at follow-up ( 1.5 years after index sample)
The number of women with CIN3+ diagnosed in either cervical biopsies or cone biopsy	The detection of underlying CIN3 or worse	at baseline ( within 3 months after index sample)
The number of women with CIN3+ diagnosed in either cervical biopsies or cone biopsy	The detection of underlying CIN3 or worse	at follow-up (1.5 years after index sample)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical accuracy (sensitivity and specificity of each triage marker and in different combinations)	sensitivity to detect underlying CIN2+ and specificity to exclude underlying CIN2+	at baseline (within 3 months after index sample)
Clinical accuracy (sensitivity and specificity of each triage marker and in different combinations)	sensitivity to detect underlying CIN2+ and specificity to exclude underlying CIN2+	at follow-up (1.5 years after index sample)
HPV genotype distribution	We will measure the distribution of hrHPV types among these older women	at baseline (within 3 months after index sample)
DS positivity rate	We will measure the DS positivity rate among these older women	at baseline (within 3 months after index sample)

Collaborators and Investigators

• Sponsor: University of Aarhus
• Collaborators: Randers Regional Hospital
• Investigators: Principal Investigator: mette tranberg, post doc, Randers Regional Hospital, Denmark

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): February 27, 2023
• Primary Completion (ANTICIPATED): February 1, 2027
• Study Completion (ANTICIPATED): February 1, 2027

Study Registration Dates

• First Submitted: January 16, 2023
• First Submitted That Met QC Criteria: February 3, 2023
• First Posted (ESTIMATE): February 14, 2023

Study Record Updates

• Last Update Posted (ESTIMATE): February 14, 2023
• Last Update Submitted That Met QC Criteria: February 3, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: mass screening; triage biomarkers
• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Uterine Cervical Neoplasms
• Other Study ID Numbers: 2704

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: This is yet to be decided.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No